With approximately 700,000 deaths annually, vector-borne diseases including malaria, place an incredible burden on health systems in low- and middle-income countries. Among vector-borne diseases, malaria is the biggest killer with approximately 405,000 deaths every year (WHO, 2018).
Despite being preventable and treatable, malaria threatens the lives of 3.2 billion people globally - nearly half of the world's population. 91% of malaria deaths occur in sub-Saharan Africa. Furthermore, children under the age of five accounted for 67% of all malaria deaths in 2018, making them a specific vulnerable group (Global Fund, 2019).
In countries where malaria is endemic, prevention is an important component of vector control. As a major global supplier of Long-Lasting Insecticidal Nets (LLINs) and Indoor Residual Spray (IRS), IDA Foundation helps to ensure populations at risk can prevent these diseases. Our assortment also includes medicines to prevent malaria in vulnerable groups, including pregnant women and infants.
Malaria infections can be treated with anti-malarial medicines. The WHO recommends the use of artemisinin-based combination therapy (ACT) in cases of drug-resistant falciparum malaria. IDA Foundation offers a complete range of antimalarial drugs including fixed dose combinations and products for severe malaria.
Since the beginning of 2019, IDA Foundation procured over 130 million LLINs, serving an estimated 260 million people in 52 countries.